"10.1371_journal.pone.0031260","plos one","2012-06-22T00:00:00Z","Binoy Appukuttan; Trevor J McFarland; Andrew Stempel; Jean B Kassem; Matthew Hartzell; Yi Zhang; Derek Bond; Kelsey West; Reid Wilson; Andrew Stout; Yuzhen Pan; Hoda Ilias; Kathryn Robertson; Michael L Klein; David Wilson; Justine R Smith; J Timothy Stout","Casey Eye Institute, Oregon Health and Science University, Portland, Oregon, United States of America","Conceived and designed the experiments: BA JTS. Performed the experiments: BA TJM JBK DB YZ KW RW A. Stout HI KR MWH YP A. Stempel. Analyzed the data: BA TJM MWH DJW JRS JTS A. Stempel. Contributed reagents/materials/analysis tools: MLK. Wrote the paper: BA TJM JRS JTS.","The authors have read the journal’s policy and have the following conflicts: Authors BA, TJM and JTS have submitted a patent for the use of RTEF-1 variants as therapy for ocular neovascular disease. Title of patent is: “RTEF-1 variants and the use thereof for inhibition of angiogenesis.” Application number: 12/134,626 Publication number: US 2009/0117119 A1 Filing date: Jun 6, 2008 A link to the patent application is given below: http://www.google.com/patents?id=ZUXGAAAAEBAJ&printsec=frontcover&dq=appukuttan&hl=en&ei=24Q4ToxDzNaIAuOGvPIO&sa=X&oi=book_result&ct=result&resnum=3&sqi=2&ved=0CCwQ6AEwAg. The authors state that this does not alter their adherence to all the PLoS ONE policies on sharing data and materials, as detailed in the guide to authors. In addition, the authors verify that the majority of the experiments/data presented in this manuscript was discovered prior to the filing of the patent and that no personal financial interest will be gained from the publication of the data presented in this manuscript. The authors have obtained funding from the National Institutes of Health to continue experiments on RTEF isoforms and verify that they are presenting the data in an unbiased fashion for peer review. All other authors declare that no competing interests exist.","2012","06","Binoy Appukuttan","BA",17,FALSE,2,8,7,4,TRUE,TRUE,TRUE,3,"11;12;13",TRUE
